Article
Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy.
Medical oncology (Northwood, London, England) - 1 Oct 2014
Bayraktar Soley, Royce Melanie, Stork-Sloots Lisette, de Snoo Femke, Glück Stefan
Abstract excerpt
The purpose of this study was to assess the correlation of the pathologic complete response (pCR) and near-complete pathologic response (npCR) between gene expression profiling using either the dataset of 150 genes as determined by BluePrint/MammaPrint versus PAM50 molecular subtyping. The samples were from patients with operable early-stage breast cancer prior to neoadjuvant chemotherapy of capecitabine plus...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.